Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Year-end report 2019

Fri, Feb 28, 2020 08:00 CET

Gothenburg, February 28 2020 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2019.Important events during the fourth quarter · In October, Vicore Pharma submitted an application to start a phase II study with C21 on cold induced vasoconstriction in subjects with systemic sclerosis (SSc). The application was approved and the first patient was recruited in December. The study is expected to be completed within one year. · In November, Vicore completed a directed share issue resulting in the proceeds of 125 MSEK before transaction costs. Important events after

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Year-end report 2019

Media